Analyst Price Targets — SLN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 28, 2024 8:03 am | Keay Nakae | Chardan Capital | $55.00 | $19.00 | TheFly | Silence Therapeutics price target raised to $55 from $42 at Chardan |
| June 28, 2024 7:44 am | Michael Ulz | Morgan Stanley | $49.00 | $19.00 | TheFly | Silence Therapeutics price target raised to $49 from $45 at Morgan Stanley |
| March 13, 2024 11:01 am | Kostas Biliouris | BMO Capital | $67.00 | $25.61 | StreetInsider | BMO Capital Reiterates Silence Therapeutics (SLN) as Top Pick, 'buy the dip' |
| December 9, 2022 7:26 am | — | Morgan Stanley | $18.00 | $15.23 | Benzinga | Morgan Stanley Initiates Coverage On Silence Therapeutics with Equal-Weight Rating, Announces Price Target of $18 |
| November 17, 2022 8:28 am | — | Chardan Capital | $29.00 | $13.21 | Benzinga | Chardan Capital Maintains Buy on Silence Therapeutics, Lowers Price Target to $29 |
Latest News for SLN
Silence Therapeutics PLC Sponsored ADR (NASDAQ: SLN - Get Free Report) has earned a consensus recommendation of "Hold" from the six brokerages that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has served as the Company's President, Chief Executive Officer and Board member since 2022, agreed by mutual consent to end his employment with the Company effective 14…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SLN.
U.S. House Trading
No House trades found for SLN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.